Tellus Therapeutics is a neonatal care company developing treatments for our most vulnerable patient population

Preterm infants are our most vulnerable patient population and are at risk for a variety of injuries that can alter normal development. During the neonatal period, the preterm infant brain is in its early stages of development. Factors influencing brain development during this time can have lifelong impacts on a child’s neurologic outcome. Specifically, neonatal events causing inflammation or oxygen deprivation can result in white matter injury (WMI) to the brain, resulting in neurodevelopmental deficits impacting a child’s motor and cognitive abilities. There are currently no treatment options for these infants. Tellus Therapeutics is developing TT-20 for preterm infants at risk for WMI, with the goal of improving neurodevelopmental outcomes for all patients treated.